Clinical TrialJul 9, 2026, 07:31 AM
CervoMed Completes Phase 2a Enrollment for nfvPPA; Data at CTAD
AI Summary
CervoMed Inc. announced the completion of enrollment in its Phase 2a study of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), a type of frontotemporal dementia (FTD). Interim biomarker data from this study has been accepted for presentation at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference in November 2026. The company expects to share the first biomarker data in early Q4 2026 and clinical data in Q1 2027, highlighting the drug's potential to address this condition for which there are currently no approved treatments.
Key Highlights
- CervoMed completed enrollment in Phase 2a study of neflamapimod for nfvPPA.
- Interim biomarker data from the study accepted for presentation at CTAD conference (Nov 16-19, 2026).
- First biomarker data for neflamapimod in nfvPPA patients expected early Q4 2026.
- First clinical data from the Phase 2a study expected in Q1 2027.
- The Phase 2a study enrolled 25 participants with nfvPPA.
- Neflamapimod received US FDA Orphan Drug Designation for FTD in 2024.
- Recent Nature Neuroscience publication supports p38α inhibition as a therapeutic approach for FTD.
Price Impact
More from CRVO